Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a non-interventional study titled ‘ELREXFIO SPECIAL INVESTIGATION- INVESTIGATION ON LONG-TERM TREATMENT’ to assess the safety and efficacy of elranatamab in patients with relapsed and refractory multiple myeloma (RRMM). The study aims to confirm the onset status of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) and evaluate adverse reactions and overall response rate (ORR) for long-term treatment.
The intervention being tested is elranatamab, a treatment designed to address RRMM by evaluating its safety and effectiveness under real-world conditions.
This observational study follows a cohort model with a prospective time perspective, focusing on gathering data on the real-world application of elranatamab without any specific allocation or masking.
The study began on July 30, 2024, with its latest update submitted on August 4, 2025. These dates are crucial as they mark the progression and ongoing nature of the study, providing a timeline for data collection and analysis.
The update on this study could influence Pfizer’s stock performance and investor sentiment positively, as successful outcomes may enhance the company’s position in the oncology market. Competitors in the multiple myeloma treatment space will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.